Magnetic Field News and Research

RSS

FDA approves Celsius RMT ThermoCool catheter for use with Stereotaxis' magnetic navigation system

Stereotaxis announced that the Celsius® RMT ThermoCool® catheter has been approved by the U.S. Food and Drug Administration for use with Stereotaxis' magnetic navigation system for the treatment of Type 1 atrial flutter. The product is the fifth advanced ablation catheter resulting from the on-going co-development agreement between Stereotaxis and Biosense Webster to design and distribute magnetically enabled catheters for mapping and ablation.

12 Jan 2010

New technique offers a low-cost alternative to make 'micromotors' for surgical instruments

Researchers at Purdue University have created a magnetic "ferropaper" that might be used to make low-cost "micromotors" for surgical instruments, tiny tweezers to study cells and miniature speakers.

6 Jan 2010

NIST and PTB join to test newly developed optical magnetic field sensor

The "magnetically best shielded room on earth" has the size of an apartment block and is located on the site of the Physikalisch-Technische Bundesanstalt (PTB), Institute Berlin. Magnetic fields such as that of the earth are kept out here as effective as nowhere else.

14 Dec 2009

DTI helps identify distorted nerve fiber bundles around brain tumors in thalamic JPA children

A new study published this week in the Journal of Neurosurgery: Pediatrics finds that operative plans for removing Juvenile Pilocytic Astrocytoma, or JPA, tumors in the thalamus of the brain can be augmented with Diffusion Tensor Imaging, or DTI. The sensitivity of DTI imaging allows for the visualization of nerve fiber bundles in the brain.

5 Dec 2009

Benign tumors in children can be augmented with Diffusion Tensor Imaging

5 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

MagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products. With this step, MagForce has now commenced the conformity assessment procedure for its Nano-Cancer ® therapy.

30 Nov 2009

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Got food poisoning? The cause might be bacterial spores, en extremely hardy survival form of bacteria, a nightmare for health care and the food industry and an enigma for scientists. Spore-forming bacteria, present almost everywhere in our environment, can also cause serious infectious diseases, such as tetanus, anthrax, and botulism.

12 Nov 2009

NIH $1 million Challenge Grant to refine cell-tracking nanotube technology

The National Institutes of Health (NIH) has awarded researchers at Rice University and the Texas Heart® Institute (THI) a $1 million Challenge Grant to refine cell-tracking nanotube technology that could make magnetic resonance imaging (MRI) up to 40 times more sensitive than existing MRIs and help guide adult stem cells within the human body to repair damaged hearts.

10 Nov 2009

Rush University Medical Center opens TMS Clinic to offer non-drug treatment for depression

Rush University Medical Center has opened the Transcranial Magnetic Stimulation (TMS) Clinic to offer patients suffering from major depression a safe, effective, non-drug treatment. TMS therapy is the first FDA-approved, non-invasive antidepressant device-based treatment clinically proven for treatment of depression.

6 Nov 2009

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma.

4 Nov 2009

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

4 Nov 2009

Manhattan Scientifics enters into a non-binding LOI with Edward R. Flynn

Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn’s patents and IP in the emerging field of nanomedicine.

21 Oct 2009

Small mechanical force induces strong biological responses in embryonic stem cells

Applying a small mechanical force to embryonic stem cells could be a new way of coaxing them into a specific direction of differentiation, researchers at the University of Illinois report. Applications for force-directed cell differentiation include therapeutic cloning and regenerative medicine.

20 Oct 2009

Much remains to be done for autism spectrum disorders, say experts

Scientific understanding and medical treatments for autism spectrum disorders (ASDs) have advanced significantly over the past several years, but much remains to be done, say experts from the Center for Autism Research at The Children's Hospital of Philadelphia who published a scientific review of the field today.

15 Oct 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

Hyper-SAGE with MRI sensitivity, a promising tool for in vivo diagnostics and molecular imaging

A new technique in Magnetic Resonance Imaging dubbed "Hyper-SAGE" has the potential to detect ultra low concentrations of clincal targets, such as lung and other cancers. Development of Hyper-SAGE was led by one of the world's foremost authorities on MRI technology, Alexander Pines, a chemist who holds joint appointments with the Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley.

12 Oct 2009

Twinkling nanostars improve optical imaging of tumors

Researchers at Purdue University have created magnetically responsive gold nanostars that may offer a new approach to biomedical imaging. The nanostars gyrate when exposed to a rotating magnetic field and can scatter light to produce a pulsating or "twinkling" effect. This twinkling allows them to stand out more clearly from noisy backgrounds such as those found in biological tissue. Alexander Wei, Ph.D., and Kenneth Ritchie, Ph.D., M.Sc., led the team that created the new gyromagnetic imaging method. The work appears in a paper published in the Journal of the American Chemical Society.

23 Sep 2009

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials.